Phase 1 studies are currently enrolling patients with multiple myeloma to evaluate the safety and efficacy of either single CAR T cell products targeting BCMA, CD138, CD38, Integrin β7 or CS1, or ten different dual-targeting combinations of these products (NCT03778346). Here, CD38 is linked to plasma cell myeloma.